Opdualag – a fixed-dose combination of LAG-3 inhibitor relatlimab and BMS' PD-1 inhibitor Opdivo (nivolumab) – was approved as a first-line therapy for unresectable or metastatic melanoma by ...

BMY posts impressive third-quarter results, with both earnings and sales beating the respective estimates. The company also ...

Q3 2024 Earnings Call Transcript October 31, 2024 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

On Thursday, Bristol Myers Squibb & Co (NYSE:BMY) posted third-quarter revenues of $11.89 billion, beating the consensus of ...

Growth portfolio primarily comprises sales from immuno-oncology drugs like Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, ...

Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood ...

It's another setback for the LAG-3 category in MSS colorectal cancer, coming after Bristol-Myers Squibb's combination of PD-1 nivolumab and LAG-3 drug relatlimab – approved as Opdualag for ...

Analyst Terence Flynn from Morgan Stanley reiterated a Sell rating on Bristol-Myers Squibb (BMY – Research Report) and decreased the ...